NASDAQ: CSTLCastle Biosciences Inc Stock
$26.15-4.10 (-13.55%)
Updated Jan 13, 2025
CSTL Price
$26.15
Fair Value Price
N/A
Market Cap
$732.39M
52 Week Low
$16.97
52 Week High
$35.84
P/E
118.86x
P/B
1.66x
P/S
2.55x
PEG
N/A
Dividend Yield
N/A
Revenue
$311.88M
Earnings
$6.08M
Gross Margin
81.9%
Operating Margin
3.73%
Profit Margin
1.9%
Debt to Equity
0.17
Operating Cash Flow
$59M
Beta
1.16
Next Earnings
Feb 26, 2025
Ex-Dividend
N/A
Next Dividend
N/A
CSTL Overview
Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma and myPath Melanoma, a proprietary GEP test to diagnose suspicious pigmented lesions. It offers test services through physicians and their patients. The company was founded in 2007 and is headquartered in Friendswood, Texas.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine CSTL's potential to beat the market
BBuy
- Stocks with a Zen Rating of Buy (B) had an average return of +19.88% per year. Learn More
Zen Rating Component Grades
C
Value
B
Growth
C
Momentum
A
Sentiment
C
Safety
C
Financials
C
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Be the first to know about important CSTL news, forecast changes, insider trades & much more!
CSTL News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CSTL scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CSTL is poor value based on its earnings relative to its share price (118.86x), compared to the US market average (29.88x)
P/E vs Market Valuation
CSTL is poor value based on its earnings relative to its share price (118.86x), compared to the US Diagnostics & Research industry average (23.46x)
P/E vs Industry Valuation
CSTL is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
There are 30 more CSTL due diligence checks available for Premium users.
Valuation
CSTL price to earnings (PE)
For valuing profitable companies with steady earnings
Company
118.86x
Industry
23.46x
Market
29.88x
CSTL is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
CSTL is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation
CSTL price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.66x
Industry
4.13x
CSTL is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CSTL's financial health
Profit margin
Revenue
$85.8M
Net Income
$2.3M
Profit Margin
2.6%
CSTL's Earnings (EBIT) of $11.63M... subscribe to Premium to read more.
Interest Coverage Financials
CSTL's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$514.6M
Liabilities
$73.5M
Debt to equity
0.17
CSTL's short-term assets ($344.77M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CSTL's short-term assets ($344.77M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CSTL's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
CSTL's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$23.3M
Investing
-$14.8M
Financing
$838.0k
CSTL's operating cash flow ($59.09M)... subscribe to Premium to read more.
Debt Coverage Financials
CSTL vs Diagnostic & Research Stocks
Castle Biosciences Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.